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ABSTRACT:
Glioblastoma (GBM) is the most malignant brain tumor where patients’ survival is only 
14.6 months, despite multimodal therapy with debulking surgery, concurrent chemotherapy 
and radiotherapy. There is an urgent, unmet need for novel, effective therapeutic strategies 
for this devastating disease. Although several immunotherapies are under development for 
the treatment of GBM patients, the use of natural killer (NK) cells is still marginal despite 
this being a promising approach to treat cancer. In regard of our knowledge on the role of 
NG2/CSPG4 in promoting GBM aggressiveness we investigated the potential of an innovative 
immunotherapeutic strategy combining mAb9.2.27 against NG2/CSPG4 and NK cells in 
preclinical animal models of GBM. Multiple immune escape mechanisms maintain the tumor 
microenvironment in an anti-inflammatory state to promote tumor growth, however, the distinct 
roles of resident microglia versus recruited macrophages is not elucidated. We hypothesized that 
exploiting the cytokine release capabilities of activated NK cells to reverse the anti-inflammatory 
axis combined with mAb9.2.27 targeting the NG2/CSPG4 may favor tumor destruction by editing 
pro-GBM immune responses. Combination treatment with NK+mAb9.2.27 diminished tumor 
growth that was associated with reduced tumor proliferation, increased cellular apoptosis and 
prolonged survival compared to vehicle and monotherapy controls. The therapeutic efficacy was 
mediated by recruitment of CCR2low macrophages into the tumor microenvironment, increased 
ED1 and MHC class II expression on microglia that might render them competent for GBM antigen 
presentation, as well as elevated IFN-γ and TNF-α levels in the cerebrospinal fluid compared to 
controls. Depletion of systemic macrophages by liposome-encapsulated clodronate decreased 
the CCR2low macrophages recruited to the brain and abolished the beneficial outcomes. Moreover, 
mAb9.2.27 reversed tumor-promoting effects of patient-derived tumor-associated macrophage/
microglia (TAM) ex vivo. Taken together, these findings indicate that NK+mAb9.2.27 treatment 
may be an amenable therapeutic strategy to treat NG2/CSPG4 expressing GBMs. We provide 
a novel conceptual approach of combination immunotherapy for glioblastoma. The results 
traverse beyond the elucidation of NG2/CSPG4 as a therapeutic target, but demonstrate a proof 
of concept that this antibody may hold potential for the treatment of GBM by activation of tumor 
infiltrated microglia/macrophages.  
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INTRODUCTION
Glioblastoma (GBM) is the most common and 
malignant brain tumor in adults, classified as grade IV 
astrocytoma by the World Health Organization (WHO) [1]. 
Despite the multimodal treatment consisting of debulking 
surgery, radiotherapy and chemotherapy, the prognosis 
remains dismal, with a median survival of 14.6 months 
[2]. The main challenge for successfully treating GBM is 
its diffuse invasion of the brain parenchyma that renders 
the tumor cells refractory to surgery, chemo-radiotherapy 
and immune surveillance, leading invariably to recurrence. 
Moreover, the molecular and cellular heterogeneity of 
GBM underlies their inherent resistance to radio- and 
chemotherapy. Thus, there is an urgent need for identifying 
cancer biomarkers that drive malignant progression 
and that may be amenable for effective combination 
immunotherapeutic approaches. Indeed there is a 
growing interest in establishing novel immunotherapeutic 
approaches to the management of GBM patients. This 
is boosted partly by the Federal Drug Administrations 
(FDA) approval of Sipuleucel-T for prostate cancer and 
Ipilimumab for metastatic melanoma treatment. Moreover, 
the continual discovery of novel tumor antigens that are 
abundantly and specifically expressed in GBM tissue 
compared to normal brain [3, 4]may spur further interest 
in vaccine based immunotherapies. 
Potential targets may also be the interactions between 
tumor cells and constituents of the microenvironment 
that regulate the bioavailability of ligands for signaling 
receptors and promotion of malignant progression. 
Amongst these, proteoglycans could impact on malignant 
progression by binding growth factors, sequestration 
of chemokines and proteases. Recently the knockdown 
of the SULF2 heparin sulfatase in astrocytoma was 
demonstrated to the diminish activity of several receptor 
tyrosine kinase (RTK) signaling pathways known to be 
active in GBM[5].  Our team previously demonstrated 
the existence of a subpopulation of GBM cells expressing 
Neuroglial-2 (NG2/CSPG4) transmembrane chondroitin 
sulfate proteoglycan, with an immature phenotype denoted 
by nestin and vimentin positivity, but not CD133 [6]. The 
gene, CSPG4, encoding the NG2 or human melanoma 
proteoglycan, is turned off upon terminal differentiation, 
but is aberrantly re-expressed by several tumor types [7-
10]. Recently, we described that 50 % of GBM patients’ 
biopsies show high levels of NG2/CSPG4 expression and 
that this was an independent prognostic factor for shorter 
patient survival [6]. These NG2/CSPG4 positive GBMs 
also corresponded to the proliferative and mesenchymal 
molecular phenotypes that are associated with poor 
prognosis [11]. In addition, we demonstrated that NG2/
CSPG4 expression by GBM cells promotes angiogenesis 
[8], cellular proliferation [12], and chemo-resistance [13]. 
In this latter study, we demonstrated that NG2/CSPG4 
expressing GBM cells were highly resistance to tumor 
necrosis factor alpha (TNF-α) mediated apoptosis due 
to elevated PI3K/Akt survival signaling. NG2/CSPG4´s 
impact on the key hallmarks of GBM and its cell surface 
expression on both tumor and neovasculature render it an 
amenable target for immunotherapy using monoclonal 
antibodies that aid the recognition and destruction of 
malignant cells via the immune system. The adoptive cell 
transfer (ACT) of autologous or allogeneic lymphocytes to 
treat cancer has demonstrated great therapeutic potential in 
early clinical trials of several solid malignancies, including 
melanoma and neuroblastoma [14, 15]. A number of 
phase I/II clinical trials have been conducted using ACT 
of lymphokine activated killer (LAK) cells or cytotoxic T 
lymphocytes (CTLs) to treat GBM. To date the efficacy 
of adoptive cellular therapies has been moderate, partly 
due to the need to generate tumor specific lymphocytes 
for each individual patient, which poses technical and 
economic hurdles for fast tracking the treatments to the 
clinic. To bypass these limitations Marcus et al., [14] 
pioneered chimeric antigen receptor (CAR) redirected T 
cells that are composed of single chain antibody fragments 
fused to T cell activating signaling motifs. This endows 
the allogeneic T cells major histocompatibility complex 
(MHC) unrestricted tumor specificity and thus, could be 
used as “ off the shelf, universal effector cells” against 
cancer in all patients. However, ACT of allogeneic T cells 
poses the inherent risk of host-versus-graft response (HvG) 
and the danger of graft-versus-host disease (HvHD). 
Among cytotoxic lymphocytes, NK cells are the 
most efficient effectors against tumors, capable of direct 
killing without prior immunization [16]. So far only two 
studies investigating purified NK cells for GBM treatment 
have been conducted, and they demonstrated a preferential 
killing of GBM stem-like cells [17, 18] purported to 
contribute to therapy resistance and recurrence. Several 
studies have demonstrated that NK cells can modulate the 
development of tumor-specific cytotoxic T lymphocytes 
and induce a T-helper 1 (Th1) cytokine profile in cancer 
[19-21]. Moreover, the immunomodulation capacity of 
NK cells through cytokine secretion could skew tumor-
associated macrophages (TAM) from anti-inflammatory 
to pro-inflammatory phenotypes [22] and was shown to 
enhance tumor immunoediting [23]. These last properties 
are essential for the success of an immunotherapy against 
GBM where up to 70 % of the tumor mass represent TAM 
polarized to the M2 phenotype that promote tumor cell 
proliferation [24], [25]. While NK cell therapies were 
shown to be effective in hematological malignancies, 
there is a paucity of studies evaluating their efficacy in 
brain tumors in vivo [26]. Whereas most studies utilize 
NK cells for their direct cytotoxicity capabilities, in the 
present study we investigated a novel approach to exploit 
the potential of NK cells to revert the immune contexture 
from anti-inflammatory to pro-inflammatory through 
cytokine release. We further investigated the therapeutic 
potential of NK cells to induce antibody dependent cellular 
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cytotoxicity (ADCC) in the brain through ligation of the 
mAb9.2.27 directed against NG2/CSPG4. The mAb9.2.27 
is one of the first monoclonals ever to be produced against 
NG2/CSPG4, as well as one of the antibodies having the 
longest track-record of being exploited to target NG2/
CSPG4-positive cancer cells in vitro and in vivo. All 
attempts to use mAb9.2.27 to abrogate tumors in vivo 
have focused upon the use of antibody complexes carrying 
cytotoxic agents, whereas no published study has clearly 
demonstrated a direct anti-neoplastic effect of the naked 
antibody. Other anti-NG2/CSPG4 antibodies have been 
reported to display an anti-tumor potential in vivo, but 
none of these have proven to be effective on glioblastoma 
and none have been extensively tested in combination 
therapy with immune cells. Thus, the present study 
provides a novel conceptual approach to the combination 
immunotherapeutic treatment of glioblastoma. Our 
findings have greater implications beyond the elucidation 
of NG2/CSPG4 as a therapeutic target, but demonstrate a 
proof of concept that mAb9.2,27 could activate cytotoxic 
functions of glioma infiltrated microglia/macrophages 
that may further hold therapeutic potential. 
The principal aims of the present paper were 
to investigate the therapeutic efficacy of combining 
adoptively transferred, purified, activated NK cells with 
passive immunotherapy using mAb9.2.27 in GBM-
bearing rats and to identify the mechanisms and cellular 
subsets mediating the anti-tumor effects. We demonstrated 
that the combination treatment with activated NK cells 
and mAb9.2.27 eradicated the tumor more efficiently 
compared to monotherapies with mAb9.2.27 or NK cells 
and vehicle-treated controls. The mechanism involved 
the recruitment of macrophages/microglia with a pro-
inflammatory phenotype into the tumor. In addition, 
activated macrophages/microglia became highly cytotoxic 
against tumor cells ex vivo in presence of mAb9.2.27 
RESULTS
Combination treatment with mAb9.2.27 and 
adoptively transferred NK cells diminishes GBM 
cell proliferation and increases survival 
We demonstrated previously that elevated levels 
of the NG2/CSPG4 proteoglycan on GBM cells and 
angiogenic vasculature is associated with a more 
aggressive disease course [6, 8, 12, 13]. We therefore 
hypothesized that perturbation of NG2/CSPG4 signaling 
with mAb9.2.27 alone or in combination with adoptively 
transferred NK cells might have therapeutic benefits for 
tumor-bearing rats. First we investigated the efficacy of the 
combination treatment in eradicating U87MG gliomas that 
are 99.2±0.2 % (n=3) NG2/CSPG4 positive, as recognized 
by mAb9.2.27 (Supplementary Fig. 1A). Four weeks after 
treatment, control untreated U87MG tumors were strongly 
contrast enhancing on T1-weighted MR images indicating 
increased angiogenesis and rapid growth compared to 
monotherapy and combination treated animals (Fig. 
1A). However, while the monotherapy groups exhibited 
initial radiological responses of reduced tumor sizes on 
T1 weighted MRI with contrast, (Fig. 1A), after 5 weeks 
both monotherapy and control tumors progressed and 
killed their hosts. The NK+mAb9.2.27 combination 
treated tumors regressed as indicated by dramatically 
diminished contrast enhancement in MR images 3 months 
post-treatment (Fig. 1A). Tumor cell proliferation was 
significantly attenuated in the combination treatment 
compared to all other groups (One way ANOVA F7.4, NK 
p=0.006, n=6; mAb9.2.27 and control p=0.001, n=5), (Fig. 
1B). The tumors treated with combined NK+mAb9.2.27 
contained significantly larger areas with apoptotic and 
necrotic tissue compared to all other treatments (One 
way ANOVA F20, df=3, p=0.0001, n=32), (Fig. 1C). 
Correspondingly, the combined treatment significantly 
prolonged the survival of the animals with a median 
survival time of 91 days compared to 52, 44, and 39 
days in the mAb9.2.27, NK cell and control groups, 
respectively (Log Rank 9.3, df=3, p=0.026, n=7), (Fig. 1D). 
In NK+mAb9.2.27 group, 60 % of the animals sacrificed 
for autopsy displayed necrosis with no visible tumor mass.
Next, we investigated the requirement for NG2/
CSPG4 recognition in NK+mAb9.2.27 therapeutic 
efficacy in U251-NG2 GBM tumors that stably 
overexpress rat NG2/CSPG4 but have a lower affinity for 
the human mAb9.2.27 as indicated by 34.5±4.2 % (n=3) 
positivity, (Supplementary Fig. 1B). T1-weighted MR 
images showed contrast agent leakage in all tumors one 
week prior to treatment. Treatment with mAb9.2.27 alone 
or in combination with NK cells diminished contrast agent 
leakage at 10 days post treatment compared to control 
tumors. However, all the tumors continued to grow as 
seen on T1-weighted MRI after 3 weeks (Supplementary 
Fig. 2A). Optical imaging demonstrated the presence 
of mAb9.2.27 retained in the tumor bed 5 days post-
infusion while the IgG2a isotype control antibodies could 
not be visualized (Supplementary Fig. 2B), indicating 
that the mAb9.2.27 was stable within the tumor for at 
least 5 days. In contrast to the U87MG tumors, Ki67 
labeling index revealed increased proliferation of the 
NK+mAb9.2.27 combination treated tumors, compared to 
control  (ANOVA F14.24, df=3, p=0.0001, n=5), mAb9.2.27 
treated tumors (p=0.0001, n=7) and NK cell treated tumors 
(p=0.001, n=6), (Supplementary Fig. 2C). However, the 
combination treated tumors also contained greater areas 
with necrotic/apoptotic cells compared to control and 
monotherapy groups (ANOVA F2.8, df=3, p=0.0001, 
n=5), (Supplementary Fig. 2D). The latter finding was 
reflected in the survival curves, as the NK+mAb9.2.27 
combination treatment marginally prolonged the median 
survival to 34.5 days compared to 24 days in NK cell 
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Figure 1: Combination NK+mAb9.2.27 treatment ablates tumor growth, prolongs survival and presented a tropism 
for cytotoxic cells in combination treated in U87MG bearing rats. (A) Longitudinal axial post-contrast T1-weighted images 
of nude rats bearing U87MG tumors treated with combination NK+mAb9.2.27, NK cell monotherapy, mAb9.2.27 monotherapy, and 
untreated controls, showing the same animal after 4, 5 weeks and 3 months post NK+mAb9.2.27 treatment. (B), (C) Plot showing the 
quantification of (B) tumor proliferation by % Ki67 labeling index and (C) cell death by % area fraction TUNEL positive apoptotic/necrotic 
cells. Data represent mean ± SEM of all tumors in the groups. ***p<0.001 and **p<0.01. (D) Kaplan –Meier survival curves showing 
surviving fraction, n=7 animals/group. (E) H&E staining of U87MG tumor with necrosis (scale bar 200µm, magnification 100X). Increased 
myeloperoxidase positive cells in mAb9.2.27 and combination treated tumors compared to control and NK treated tumors (scale bar 100µm, 
magnification 200X). High granzyme B positivity in combination treated tumors (scale bar 100µm, magnification 400X). Quantification of 
(F) MPO and (G) granzyme B positive cells. Data in (F) and (G) represent mean SEM from all tumors in the groups. *p<0.05, **p<0.001. 
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monotherapy (p=0.0018, n=6), 32 days in mAb9.2.27 
monotherapy (p=0.014, n=5) and 29 days in the vehicle-
treated controls, (p=0.0011, n=4) at the termination of the 
experiment. Thus, the difference in therapeutic efficacy 
measured as median survival of the animals treated with 
NK+mAb9.2.27 in the U87MG (91 days) versus U251-
NG2 (34.5 days) tumors might be due to the specificity of 
NG2/CSPG4 recognition by mAb9.2.27. 
Differential recruitment of activated immune 
cells expressing cytotoxic granules regulates 
the therapeutic response in NK+mAb9.2.27 
combination therapy.
Histological analyses of U87MG tumors revealed 
that while untreated control and NK cell monotherapy 
treated tumors were angiogenic with no discernible 
Figure 2: Differential macrophage/microglia phenotypes in response to treatment in U251-NG2 tumours. (A) Upper panels, 
H&E staining showing tumor-brain boarders with varying amounts of large foamy cells (white) in response to mAb9.2.27 monotherapy 
and NK+mAb9.2.27 combination treatment (scale bar 200 µm, magnification 100 X). (A) Lower panels show higher magnification of the 
confrontation zone (scale bar 200 µm, magnification 200 X), (B) Upper panel show quantification of area fraction CD8+ cells in control, 
monotherapy NK cells, mAb9.2.27 as well as in NK+mAb9.2.27 combination treatment, lower panel shows quantification of area fraction 
ED1+ cells, in the same groups as above. Data represent mean ±SEM from all tumors in the groups. (C) Immunolabeling of CD8 shows 
abundant recruitment via vascular cuffs and choroids plexus in NK+mAb9.2.27 and mAb9.2.27 treatments, (arrowheads) respectively. 
Control and NK treated tumors show CD8+ cells that are restricted to tumor/brain periphery scale bar 200 µm, magnification 200X. (D) 
Double labeling for CD8 (brown) and ED1 (red) show abundant double positive macrophage/microglia in the tumor core (T) as well as 
those migrating from the brain (B, insert). mAb9.2.27 treated tumors show predominantly ED1 single positive, controls show CD8 single 
positive, and NK monotherapy shows fewer CD8/ED1 double positive cells that remain at the tumor/brain periphery  (scale bar 100 µm, 
magnification 400 X).
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central necrosis, NK+mAb9.2.27 and mAb9.2.27 treated 
tumors exhibited large central necrosis, densely filled 
with leucocytes (Fig. 1E). The necrotic areas showed 
an intense myeloperoxidase (MPO) activity in the 
combination treated tumors, whereas it was markedly 
attenuated in NK cell monotherapy and control groups 
(One-way ANOVA 14.97, df=3, p=0.0018, n=5), (Fig. 1E 
and 1F). Granzyme B was also abundantly expressed 
after NK+mAb9.2.27 treatment in areas adjacent to focal 
necrosis/apoptosis compared to the control tumors (One 
way ANOVA 13.21, df=3, p=0.0042, n=4), (Fig. 1E and 
1G). Similar to U87MG tumors, histological analyses of 
U251-NG2 tumors also revealed that both mAb9.2.27 
and NK+mAb9.2.27 treated tumors exhibited extensive 
tissue necrosis, packed with leucocytes (supplementary 
Fig. 3A), and more abundant MPO expressing cells were 
present in the NK+mAb9.2.27 treated tumors compared 
to NK cell and mAb9.2.27 monotherapy, as well as and 
control tumours (One-way ANOVA 4.07, df=3, p<0.0001, 
n=5), (supplementary Fig. 3A and 3B). Granzyme B was 
abundantly expressed in the mAb9.2.27 treated tumors 
compared to NK cell monotherapy and controls in areas 
adjacent to focal necrosis/apoptosis (One-Way ANOVA19.90 
df=3, p=0.0002, n=5), (Supplementary Fig. 3A and 
Figure 3: In vivo depletion of bone marrow derived macrophage abrogates therapeutic benefit from combined 
NK+mAb9.2.27 treatment. (A) Longitudinal axial post-contrast T1-weighted and T2-Weigted MRI images of nude rats bearing 
P3-30 tumors treated with combination NK+mAb9.2.27, vehicle (PBS/liposomes) control, and NK+mAb9.2.27 treated animals given 
weekly intraperitoneal clodronate encapsulated liposomes. (B) H&E of representative animals from the vehicle control, NK+mAb9.2.27 
combination and NK+mAb9.2.27+clodronate (Scale bar 200 µm, Magnification 100 X). (C) Representative Ki67 labeling in vehicle 
control, NK+mAb9.2.27 combination and NK+mAb9.2.27+clodronate treated animals (Scale bar 100 µm, Magnification 200X). (D) % 
Ki67 labeling index and (E) quantification of area fraction TUNEL positive apoptotic/necrotic cells. Data in (D) and (E) represent mean 
±SEM of all tumors in the groups, **p<0.01 and *p<0.05. (F) Kaplan –Meier survival curves of NK+mAb9.2.27 treated and control tumor 
with or without macrophage depletion by clodronate, showing surviving fraction, n=8 animals/group.
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3C). Interferon-γ was only expressed in the mAb9.2.27 
and NK+mAb9.2.27 combination treated tumors 
(supplementary Fig. 3A). Collectively, these data indicate 
a tropism for activated immune cells with the capacity to 
secrete cytotoxic granules within tumor in the mAb9.2.27 
and NK+mAb9.2.27 treated rats. 
Next, we aimed to identify the cell populations 
implicated and delineate the mechanisms mediating 
the therapeutic effect of the combination treatment. 
Histological analysis revealed striking clusters of large 
foamy cells at the periphery and within the core of the 
mAb9.2.27 and NK+mAb9.2.27 treated U251-NG2 
tumors that were markedly diminished in the control and 
NK cell treated tumors (Fig. 2A). At perivascular cuffs 
and choroid plexus, CD8+ cells were most pronounced in 
the mAb9.2.27 monotherapy and NK+mAb9.2.27 treated 
tumors compared to the control (One-Way ANOVA F11.0, 
df=3, p=0.0011, n=5) and NK cell monotherapy tumors 
Figure 4: Increased recruitment of ED1+ activated macrophage/microglia in NK+mAb9.2.27 treated tumors. 
(A) ED1 labeling in P3-30 bearing animals in the tumor core vs. periphery in vehicle control, NK+mAb9.2.27 combination and 
NK+mAb9.2.27+clodronate treated animals, (scale bar 100 µm, magnification 200 X). (B) The quantification of positive area fraction 
for ED1 and Iba1 in tumor core and periphery in vehicle control, NK+mAb9.2.27 combination and NK+mAb9.2.27+clodronate treated 
animals. (C) Quantification of CD8+ area fraction in vehicle control, NK+mAb9.2.27 combination and NK+mAb9.2.27+clodronate treated 
animals (D) Flow cytometric representative dot plot showing the gating of cell populations from rat brain cell suspension expressing 
CD11b/c and CD45, permitting the differentiation of macrophages (CD45highCD11b/c+) and microglia (CD45lowCD11b/c+). (E) Upper panel, 
% microglia cells expressing MHC class II, ED1 and ED2. Lower panels, mean fluorescence intensity histograms as % of Max of data in 
(E). (F) Percentages of CCR2+ macrophages (right) and mean fluorescence intensity as % of max for CCR2 (left). The data in (B), (C), (E) 
and (F) represent mean ±SEM from all tumors in the groups, ***p<0.001,  **p<0.01 and *p<0.05.
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(One-Way ANOVA F11.0, p=0.0001, n=5), where the 
CD8+ cells were restricted to the tumor/brain periphery 
(Fig. 2B and 2C). No significant difference in the 
abundance of phagocytic ED1+ cells across the different 
treatment groups was found in the U251-NG2 tumors 
(Fig. 2B). However, the majority of CD8+ cells in the 
NK cell monotherapy and combination therapy tumors 
co-expressed ED1. Moreover, while CD8+ED1+ cells 
deeply infiltrated the combination treated tumors, these 
cells remained at the tumor/brain border in the NK cell 
monotherapy (Fig. 2D). In contrast, CD8-ED1+ cells 
densely infiltrated the mAb9.2.27 treated tumors, while 
the control tumors contained predominantly CD8+ED1- 
cells (Fig. 2D). The tropism for CD8+ED1+ cells in the 
combination treated tumors was also confirmed in the 
U87MG tumors (Supplementary Fig. 6A-D). CD8+ cells 
were more abundant in the NK+mAb9.2.27 treated tumors 
compared to monotherapy and controls (One-Way ANOVA 
19.24, p=0.0002, n=5, (Supplementary Fig 4C). Likewise, 
ED1+ cells were most abundant after NK+mAb9.2.27 
treatment (Two-Way ANOVA t3.928, p=0.0003, n=5), 
(Supplementary Fig 4D). As CD8 and ED1 markers can 
be expressed by both microglia and macrophages [27] 
that are difficult to distinguish by immunohistochemistry, 
we systemically depleted macrophages by intraperitoneal 
injection of clodronate once a week for 4 weeks, starting 
at the day of the treatment.
Macrophage depletion by clodronate 
treatment abolishes the therapeutic response in 
NK+mAb9.2.27 combination therapy.
To investigate further the mechanism leading to 
tumor regression, we utilized a unique GBM animal model 
developed in our laboratory where patient GBM biopsy 
spheroids are serially propagated in vivo over several 
generations. The resultant xenografts retain the genetic 
background, cellular heterogeneity and biological features 
of the original patient tumor [28]. P3-30 GBM cells 
express elevated levels of NG2/CSPG4 (93.3±3.2 %, n=3), 
(Supplementary Fig. 1C). As observed with the U87MG 
tumors, the combination therapy diminished P3-30 lesions 
volumes including vasogenic edema on T2- and solid 
tumor sizes on T1-weighted MR imaging, respectively, 
compared to the vehicle treated control group. The 
macrophage depletion abrogated this therapeutic effect as 
indicated by increased lesion volumes including tumor and 
vasogenic oedema on T2-, as well as solid tumor volume 
on T1-weighted MR imaging respectively (Fig. 3A). The 
NK+mAb9.2.27 treated tumors had larger regions with 
tissue necrosis compared to the control and clodronate 
treated group that exhibited typical pseudopalisading 
necrosis and angiogenic vasculature (Fig. 3B). Moreover, 
the clodronate NK+mAb9.2.27 treated tumors had 
strikingly numerous mitotic figures and significantly 
increased tumor proliferation indicated by elevated Ki67 
labeling index compared to NK+mAb9.2.27 treated 
animals (One-Way ANOVA F11.19, df=2, p=0.0011, n=5), 
(Fig. 3C-D). The macrophage depletion also significantly 
reduced the fraction of apoptotic/necrotic cells compared 
to vehicle treated controls, and NK+mAb9.2.27 tumors 
(One-Way ANOVA F 7.75, p=0.0079, n=4), (Fig. 3B and 
3E). The NK+mAb9.2.27 treatment prolonged animal 
survival compared to control, with median survival of 46 
days versus 38.5 days respectively (Log Rank10.06, df=1, 
p=0.0015, n=7), (Fig. 3F). However, the macrophage 
depletion abrogated this increase of animal survival, with 
a median survival of 40.5 days (Log Rank 9.8, df=1, 
p=0.0017, n=8), (Fig. 3F). These results demonstrated 
the role of macrophages in therapeutic effect of 
NK+mAb9.2.27, as their depletion using clodronate 
diminished the animal survival.
Macrophage depletion by clodronate treatment 
abolishes recruitment of ED1+ macrophage to 
the tumor core of NK+mAb9.2.27 combination 
therapy.
The NK+mAb9.2.27 treatment increased the tropism 
of ED1+ cells into the tumor core compared to vehicle 
treated controls (Two-Way ANOVA t3.991, p=0.013, n=4) 
and macrophage depleted NK+mAb9.2.27 treated tumors 
(Two-Way ANOVA t4.276, p=0.01, n=4), (Fig. 4A and 4B). 
Iba1, the calcium binding protein expressed by activated 
and phagocytic macrophage/microglia was also elevated 
in the core of the combination treated tumors compared 
to vehicle treated control (Two-Way ANOVA t4.633, 
p=0.01, n=4), and macrophage depleted tumors (Two-
Way ANOVA t3.235, p=0.0243, n=4), (Fig. 4B). Significant 
numbers of CD8+ cells were recruited into the tumor 
microenvironment after the NK+mAb9.2.27 treatment 
(One-Way ANOVA t7.482, p=0.0001, n=5), (Fig. 4C), as was 
the case for U87MG and U251-NG2 tumors. Remarkably, 
macrophage depletion by clodronate injection abrogated 
this ED1 recruitment compared to NK+mAb9.2.27 treated 
animals (Two-Way ANOVA t34.276, p=0.013, n=4). The 
CD8+ cells recruited to the NK+mAb9.2.27 treated tumor 
were significantly elevated compared to controls and 
NK+mAb9.2.27 with macrophage depletion (One-Way 
ANOVA 18.5, p=0.0001, n=5), (Fig. 4A-C). 
NK+mAb9.2.27 combination therapy promotes 
the recruitment of macrophage and microglia 
with a pro-inflammatory phenotype.
In order to investigate the subtype of cells 
expressing ED1 and CD8, we further investigated 
the phenotype of brain immune cells by 9 colors 
multiparametric flow cytometry on brain cell suspensions 
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obtained from P3-30 controls, or NK+mAb9.2.27 treated 
tumors with or without clodronate administration. 
The cellular populations representing macrophages 
(CD45highCD11b/c+) and microglia (CD45lowCD11b/c+) 
were distinguished (Fig. 4D). We could demonstrate that 
microglia increased ED1 expression after NK+mAb9.2.27 
treatment, compared to vehicle treated controls and 
concomitant NK+mAb9.2.27 and clodronate treatment 
(Two-way ANOVA t3.64, p<0.001, n=6 and t3.33, p<0.05, 
n=4), (Fig. 4E). In the other hand, the NK+mAb9.2.27 
combination treatment significantly increased MHC class 
II expression by microglia compared to controls (Two-way 
ANOVA t3.7, p<0.01, n=6), (Fig. 4E). In addition, while 
microglia from NK+mAb9.2.27 treated tumors expressed 
low levels of the scavenger receptor ED2, microglia 
from macrophage-depleted and untreated animals had 
significantly increased ED2 levels (Two-way ANOVA t3.45, 
p<0.01, n=6). We observed that 60 % of brain macrophage 
expressed ED1 following NK+mAb9.2.27 combination 
treatment, which correspond to its expression in control 
animals. The proportion of macrophages expressing 
CCR2 was significantly decreased after NK+mAb9.2.27 
therapy (Two tailed T-test, p=0.042, n=6), (Fig. 4F). 
However, both microglia and macrophage did not express 
CD8 extra-cellularly. These data might indicate that the 
therapeutic efficacy of NK+mAb9.2.27 combination 
treatment was mediated by increased recruitment of 
ED1+CCR2low macrophages, which then differentiate 
into (or activate) ED1+ED2lowMHCIIhigh microglia 
in the tumor microenvironment. These phenotypic 
modifications of macrophage/microglia suggested the 
elaboration of a pro-inflammatory environment following 
the NK+mAb9.2.27 treatment. As evidence we found 
that the classical T-helper 1 pro-inflammatory cytokines, 
IFN-γ and tumor necrosis factor alpha (TNF-α) were 
up-regulated in the cerebrospinal fluid (CSF) from the 
NK+mAb9.2.27 combination-treated animals whereas the 
immunosuppressive cytokine IL-10, as well as IL-6 and 
IL-1β were more abundant in the CSF from the untreated 
animals (Table 1). In addition, although not statistically 
significant, in the plasma there was a tendency for 
decreased IL-10 (38±25.5pg/ml, n=7 vs. 2.4±2.4pg/ml, 
n= 6) and TNF-α (25.6±14.2pg/ml, n=7 vs. 0pg/ml, n= 6) 
levels following treatment.
mAb9.2.27 and IFN-γ-activated microglia are 
more cytotoxic to GBM cells than NK cells.
In order to investigate the mechanisms of the 
synergistic mAb9.2.27 and NK cell cross-talk with 
microglia, the cytotoxicity of resting microglia and 
NK cells with and without mAb9.2.27 was tested in 
NG2/CSPG4 positive GBM cells in vitro. First, we 
observed that activated NK cells in contact with GBM 
cells produced IFN-γ, as revealed by intracellular flow 
cytometry (Two tailed T-test, NK cells alone vs. NK 
cells+U87MG p=0.0043, n=5 and vs. HF66 p=0.0095, 
n=4), (Fig. 5A). This was corroborated by increased IFN-γ 
and TNF-α released into the supernatant culture medium 
from NK cells in contact with GBM cells compared to 
supernatants from tumor cells only, (IFN-γ: One-Way 
ANOVA6.54, p=0.03; n=11; and TNFα: One-Way ANOVA 
9.59, p=0.0083; n=11). Correspondingly, the killing 
capacity of resting microglia against U87MG GBM cells 
was increased by overnight activation with IFN-γ and 
against target pre-incubated with mAb9.2.27 compared 
to the cytotoxicity of resting microglia with IgG2a 
isotype control (IC) (One-Way ANOVA, p<0.05, n=5 and 
p<0.05, n=4 respectively), (Fig. 5B). Interestingly, there 
was no cumulative effect of IFN-γ and the mAb9.2.27 
on the cytotoxicity of microglia. Indeed the cytotoxic 
capacity of microglia following activation with IFN-γ 
in absence of mAb9.2.27 was not significantly different 
from their killing capacity in presence of this mAb, with 
respectively 37.8 ±4.2 % and 43.2±5.9 % U87MG lysis 
(Fig. 5B). In contrast, there was no significant difference 
between cytotoxicity of IL-2 activated NK cells in the 
presence or absence of mAb9.2.27 against all GBM cell 
lines tested (Fig. 5C). The cytotoxicity of microglia and 
activated NK cells was also tested against the HF66 
GBM cells lines, recognized by mAb9.2.27 at almost 
100 %, and the previous results with U87MG were 
confirmed. Activation of microglia by IFN-γ , overnight 
or during 5 days rendered them highly cytotoxic against 
GBM, whereas culture with GBM conditioned medium 
promoted the survival of HF66 GBM cells, consistent with 
microglial M1- and M2-like physiology and phenotype, 
(Supplementary Fig. 5A and B respectively). As was the 
case for U87MG, the mAb9.2.27 abrogated the survival 
of HF66 tumor cells, mediated by M2-like differentiated 
microglia (Supplemental Fig. 5B). Moreover, NK cells 
preferentially killed the differentiated M2-like microglia, 
whereas M1-like microglia was more resistant to NK 
cell lysis (Supplementary Fig. 5C). Collectively, these 
data indicate that mAb9.2.27 could mediate ADCC by 
Table 1: Concentration of cytokines in CSF 
of vehicle control and NK+mAb9.2.27 treated 
rats. Concentrations of IL-1α, IL-6, IL-10, 
IFN-γ and TNF-α are given in pg/ml.
Vehicle Control NK+ mAb9.2.27
Mean SEM n Mean SEM n
IL1-α 684.5 290.2 2 50.2 29.0 3
IL6 4593.0 2256.7 2 125.2 125.2 3
IL-10 25617.9 25617.9 2 0.0 0.0 3
IFN-γ 0.0 0.0 2 21.9 13.5 3
TNF 0.0 0.0 2 110.9 100.9 3
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Figure 5: IFN-γ and mAb9.2.27 increase cytotoxicity of microglia against GBM. (A) Upper panel: dot plot showing IFN-γ 
secretion in IL-2 activated NK cells in contact with U87MG cells, Lower panel: quantification of IFN-γ secretion in IL-2 activated NK 
cells co-cultured with U87MG or HF66 at ratio 2/1 for 18 h. (B) % lysis of U87MG in vitro by microglia from naïve LEWIS rats following 
activation with IgG2a isotype control, IFN-γ or/and mAb9.2.27. (C) % lysis of U87MG in vitro by NK cells in the presence of IgG2a isotype 
control  or mAb9.2.27. (D-E) Ex vivo purified rat (D) and patient (E) macrophage/microglia from tumor microenvironment were investigated 
for cytotoxicity against P3-30 tumor pre-incubated or not with mAb9.2.27. Human TAMs were phenotyped for CD45+CD11b+CCR2 
expression (E dot plot: CD45+ against CD11b+. E Histogram: isotype control grey histogram, CCR2 black histogram). Lower panel: % 
lysis of P3-30 tumor by ex vivo TAM from patient GBM following activation with IgG2a isotype control, or mAb9.2.27. (F) Cytotoxicity 
of rat TAMs was also investigated after 96 h (F) incubation with 100 ng/ml of IFN-γ. Cell viability was determined by flow cytometry using 
TOPRO-3 as supravital dye. Data are plotted as mean ±SEM, **p<0.01, *p<0.05. (G) Adoptively transferred NK cells as initiators of GBM 
destruction: schematic representation of the in vivo and in vitro experimental findings.
In vivo: combination NK+mAb9.2.27 treatment leads to increased infiltration of the tumor by microglia and 
macrophages with pro-inflammatory phenotypes, with respectively ED1highED2low MHC class IIhigh and ED1+CCR2low 
molecular expression. This was associated with increase of pro-inflammatory cytokines in the CSF of NK+mAb9.2.27 treated animals, 
as well as diminution of cellular proliferation and increased tumor cell apoptosis. This resulted in increased animal survival that was 
abolished by depletion of systemic macrophages by injection of liposome-encapsulated clodronate. In vitro: activated NK cells induced 
cellular cytotoxicity against GBM (1). The NK cells/GBM interaction led to IFN-γ secretion by NK cells (2). This cytokine inhibited tumor 
survival promoted by tumor-associated macrophages/microglia (3). NK cells efficiently killed anti-inflammatory M2-like microglia (4). 
Moreover, mAb9.2.27 inhibited tumor survival mediated by tumor associated macrophages/microglia (5).
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microglia but not by NK cells in vitro. 
mAb9.2.27 and IFN-γ abrogate tumor-promoting 
effect of tumor-associated macrophage/microglia 
ex-vivo.
 Since our in vivo results demonstrated that 
mAb9.2.27 monotherapy slowed down tumor growth in 
the initial phases, we investigated whether mAb9.2.27 
could impact on macrophage/microglia function directly. 
These macrophage/microglia were purified from the 
brain of P3-30 tumor bearing rats and examined for 
their cytotoxic capacity ex vivo against P3-30 cells pre-
incubated or not with mAb9.2.27, and after 18 h or 96 h 
of culture in the presence of IFN-γ. The TAM promoted 
P3-30 tumor survival ex vivo, indicated by a diminution of 
its spontaneous death in culture, presented as a negative 
percentage of lysis (Fig. 5D).   P3-30 tumor cells became 
susceptible to rat TAMs cytotoxicity in the presence of 
mAb9.2.27 (One-Way ANOVA, p<0.01, n=6), (Fig. 5D). 
Remarkably, this effect was reproduced using patient 
GBM derived TAM (Fig. 5E) defined as CCR2high (Fig. 5E 
histogram) indicating the robust capability of mAb9.2.27 
to inhibit tumor promoting effect of TAMs.  Finally, 
although rat TAM failed to inhibit the tumor survival 
after 18 h in culture with IFN-γ, a prolonged activation 
to 96 h did significantly inhibit tumor survival (One-Way 
ANOVA, p<0.01, n=4), (Fig. 5 F). The conclusions from 
the in vivo and in vitro studies are summarized in the 
schematic figure 5G.
DISCUSSION
It is established that gliomas, like many cancers, 
develop multiple strategies to evade detection and 
destruction by the immune system. One of these 
mechanisms involves the recruitment of macrophages/
microglia and their maintenance in an anti-inflammatory 
(M2-like) state, through the secretion of tumor-associated 
factors likeTGF-β or prostaglandin E2, which promote 
tumor growth, migration and angiogenesis [29].  Many 
new therapeutic strategies have the ambition to skew 
M2-like TAM to M1-like phenotypes with anti-tumoral 
properties [30, 31]. We investigated a novel combination 
immunotherapeutic strategy to treat GBM using 
intratumoral administration of mAb9.2.27 against human 
NG2/CSPG4 with activated NK cells.
We treated human U87MG and U251-NG2 GBM 
cell lines xenografted in athymic nude rats. While the 
treatment significantly increased survival in both models, 
the U251-NG2 tumors exhibited only partial responses. 
As mAb9.2.27 labeled almost 3-fold less U251-NG2 cells 
than U87MG cells, the modest effect of the combination 
treatment on the U251-NG2 tumors might be expected 
and reinforces the specificity of the mAb9.2.27 in 
the therapeutic response. Moreover it emphasizes the 
importance of the presence of an interaction between 
mAb9.2.27 and NG2/CSPG4 antigen in future clinical 
applications. In addition, we used a more relevant model 
based on rats bearing patient derived GBM biopsy 
established to be more therapy resistant due to their high 
cellular heterogeneity.  Although several mouse models of 
brain tumors have been engineered by altering signaling 
pathways that are disrupted in human gliomas (reviewed 
in [32]), our patient derived xenografts retain the cellular 
heterogeneity, invasive, angiogenic and comparative 
genomic hybridisation (cGH) gene profiles as the original 
tumor [33]. Our results demonstrated that NK+mAb9.2.27 
treatment led to increased animal survival through 
the recruitment of ED1 positive cells via the choroid 
plexus into the tumor, in addition to increased numbers 
of cells with heightened capacity to secrete cytotoxic 
components such as myeloperoxidase, granzyme B and 
IFN-γ.  The difference in efficacy between the U87 and 
P3-30 combination treated xenografts might be expected 
when treating homogenous cell line versus heterogenous, 
patient-derived GBM xenografts. However, confirming 
therapeutic efficacy using different model systems adds 
robustness to our findings. The combination treatment 
prolonged survival of P3-30 xenografts from 39 to 
46 days, representing an increase in survival of 18 %. 
However, the median survival after GBM treatment in 
contemporary patient studies is 14.6 months. Thus, this 
18 % increase amounts to 2.5 months if extrapolated to 
a clinical setting. When we consider the very few and 
small improvements in prognosis for GBM patients over 
the last 5 decades, this 18 % longer survival might indeed 
have clinical significance and realistically highlight the 
challenges of treating human cancers with high degree of 
heterogeneity.
Furthermore, we could demonstrate that the 
combination treated animals had elevated concentrations 
of the pro-inflammatory cytokines IFN-γ and TNF-α in 
their CSF and diminished levels of anti-inflammatory 
cytokines such as IL-10 compared with control animals. 
These results indicated that the intra-tumoral treatment of 
NK+mAb9.2.27 modified the tumor microenvironment 
from anti-inflammatory to pro-inflammatory one 
resulting in tumor regression. This massive recruitment 
of inflammatory cells into the tumor is reflected by the 
MR images at 3 and 4 weeks in the U87MG tumors in 
vivo, where increased lesion size could be demonstrated 
by T1-weighted MRI. Smith et al. [34] previously reported 
this phenomenon as the flare effect following intralesional 
immunotherapy with activated lymphocytes and IL-
2, in patients with recurrent high grade astrocytomas 
[34]. Apparent worsening MRI imaging directly after 
therapy indicated by increased nodular enhancement, 
edema, and mass effect [7, 34] characterized the flare 
effect. This phenomena was also reported following 
gene therapy [35], convection enhanced delivery of 
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cytokines [36] or after placement of the GliaSite radiation 
therapy system [37] to treat brain tumors.  The flare 
effect highlights the challenges of using the Macdonald 
´s radiological response criteria for assessing therapeutic 
efficacy after immunotherapy [38].  The immune cell 
recruitment characterized by hyper-intense lesions on T1-
weighted MRI might easily be misinterpreted as tumor 
progression whereas in reality, it represents a pseudo-
progression. Other measures of immune responses have 
been demonstrated as independent predictive factors for 
favorable immune responses after immunotherapy [39]. 
Paradoxically, vitiligo is still reported as an adverse event 
in clinical trials evaluations, however, its presence strongly 
portends enhanced survival in melanoma patients. More 
research is required to develop clinically reliable methods 
for evaluating response to successful immunotherapy. 
In contrast to untreated animals, microglia from the 
NK+mAb9.2.27 combination treated animals up-regulated 
MHC class II molecules and ED1 expression, rendering 
them competent for presentation of GBM antigens [40]. 
In addition, microglia expressing ED2 scavenger receptor 
were diminished by the combination NK+mAb9.2.27 
treatment, indicating a reduction of perivascular microglia 
postulated to facilitate GBM progression [41]. In parallel 
the NK+mAb9.2.27 treatment decreased the proportion 
of macrophages expressing CCR2, a subpopulation 
already proven to promote GBM invasiveness [42]. These 
characteristic features of activated cytotoxic cells, as well 
as the increased survival were abrogated by depletion of 
circulating macrophages with clodronate treatment. This 
indicated that the beneficial outcomes were mediated by 
the recruitment of pro-inflammatory macrophages from 
the periphery to the tumor. Nevertheless, we cannot 
exclude the possibility that dendritic cells play a role in the 
therapeutic efficacy, as liposome-encapsulated clodronate 
was shown to selectively induce apoptosis of macrophages 
[43] and phagocytic dendritic cells [44]. Indeed, both cell 
types share the expression of CD45highCD11b/c+ and only 
OX-62 can distinguish dendritic cells from macrophages 
[45-47]. Unfortunately, we did not use anti-OX-62 
(CD103) mAb in our flow cytometry staining to be able to 
differentiate MHC class II positive activated macrophages 
from dendritic cells. Taken together our results indicate 
that the combination treatment permits the infiltration 
of ED1+CCR2low macrophages, which then differentiate 
into or promote ED1+ED2lowMHC II+ microglia that favor 
tumor destruction by creating pro-inflammatory tumor 
microenvironment.
We propose that implantation of activated NK cells 
was the decisive element required for the development 
of the pro-inflammatory environment. Neither NK cells 
nor mAb9.2.27 monotherapy significantly prolonged 
survival, but since combination treatment did, we suggest 
that a synergistic action of NK cells and mAb9.2.27 
facilitated tumor regression.  Recently, NK cells were 
demonstrated to mediate the therapeutic efficacy by 
ADCC of a chimeric antibody directed against an 
intracellular antigen, phosphatase of regenerating liver-3 
(PRL-3), in nude mice. Depletion of NK cells with asialo 
GM-1 antibodies abolished the therapeutic efficacy [48] 
underscoring the therapeutic impact of NK cell induced 
ADCC. Using T1-weighted sequences we established 
in the present study that the mAb9.2.27 treated tumors 
exhibited reduced leakage of contrast agent from the 
tumor vasculature. This effect of mAb9.2.27 is likely 
due to blocking the angiogenic potential of NG2/CSPG4 
expressing pericytes on the tumor vasculature. Although 
some provocative studies reported that immature 
GBM stem-like cells are capable of differentiating into 
functional vascular endothelium and might contribute 
to tumor angiogenesis[49, 50]recent systematic studies 
demonstrated using chromogenic in situ hybridization on 
intact tissue that neoplastic cells are a rare component in 
human GBM microvasculature, do not incorporate into the 
vessel wall or express CD34 [51], Thus, blocking NG2/
CSPG4 signaling may have decreased the angiogenic 
capacity of the tumors mediated by pericytes. We have 
previously shown that NG2/CSPG4 was located on 
the tumor cells as well as their angiogenic vasculature 
on pericytes [8, 52]. Others have demonstrated that 
targeting NG2/CSPG4 on these pericytes diminished 
mouse pathological retinal and corneal angiogenesis 
[53]. Recently, Wang et al. demonstrated in a xenograft 
model of breast cancer that the administration of the 
anti-NG2/CSPG4 mAb225.28 diminished tumor growth, 
associated with reduced proliferation and vascular density, 
and increased apoptosis [13]. Moreover, we proved that 
purified GBM associated macrophage/microglia, from rat 
and acutely dissociated patient biopsy, were no longer able 
to promote tumor survival in presence of mAb9.2.27 ex 
vivo. It would be interesting to study further this capacity 
of mAb9.2.27 to modulate macrophage polarization and 
to examine the mechanisms involved. Numerous studies 
have reported that ligation of the Fc receptor induces 
the transcription of several genes in macrophages that 
contribute to subsequent inflammatory and immune 
responses [54]. The mechanisms of macrophage/microglia 
ADCC against brain tumors are not well documented, 
nonetheless a study from the 90’s demonstrated microglia 
ADCC using an anti-EGFR mAb [55]. Furthermore, using 
an FcγR deficient mouse model of brain metastatic B16 
tumor expressing EGFRvIII, Sampson et al. demonstrated 
that the survival advantage of anti-EGFRvIII mAb 
treated animals was FcγR dependent [56]. As resident 
macrophage/microglia are known to express FcγR [57], 
these findings support our data implicating a subpopulation 
of macrophage/microglia in the tumor destruction. Since 
NK cells alone were not able to induce potent ADCC, but 
were required for the synergistic effects of the combination 
therapy, we hypothesized that NK cells could be involved 
in generation of tumor immunoediting, as recently 
described by O´Sullivan et al. [23]. We demonstrated that 
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activated NK cells were able to secrete TNF-α and IFN-γ 
in contact with GBM. However, the direct effect of TNF-α 
expressing GBM cells is unclear since we previously 
demonstrated that these cells were resistant to TNF-α 
mediated apoptosis due to augmented PI3K/Akt and 
NFκB survival signaling [13]. Indeed, the Fernandez-Luna 
group showed that blockade of NFκB in glioma initiating 
cells (GICs) with genetic strategies or small molecule 
inhibitors induced cell cycle arrest, cellular differentiation 
and senescence [58]. However as these effects were 
described for these so-called GICs, the implications of 
their findings remain to be proven since the ontogeny of 
GBM from GICs and the extent to which GBM cells are 
capable of undergoing senescence remain controversial. 
Interferon-γ was previously shown to switch human 
immunosuppressive TAMs into immunostimulatory cells 
[59], to upregulate their expression of MHC class II [60] 
and co-stimulatory molecules [61]. The macrophages 
were subsequently more phagocytic [62] and released 
more cytotoxic pro-inflammatory cytokines [59, 63], 
nitric oxide [28] and MPO [64]. In this study we found 
that IFN-γ may also inhibit the survival promoting 
effect of TAMs on P3-30 GBM in vitro. However it is 
difficult to translate this finding in vivo as we may have 
used a high concentration of IFN-γ in vitro (100 ng/ml) 
compared to the concentration we found in the CSF (20 
pg/ml). Indeed, lower levels of IFN-γ (1 to 20 ng/ml) 
were shown to promote microglia neurogenesis while 
high concentrations could be neurotoxic (50 ng/ml) 
[65, 66]. Future studies should address this question. In 
addition, we showed that NK cells preferentially killed 
the differentiated M2-like microglia, whereas M1-like 
microglia were more resistant to NK cell lysis. These 
results are similar to those from a recent work of Bellora 
et al. showing that mouse activated NK cells preferentially 
kill M2 macrophages rather than M1 macrophages [67]. 
To summarize, our findings demonstrate that activated 
NK cells could modulated the anti-inflammatory tumor 
microenvironment to a pro-inflammatory contexture 
facilitating the recruitment and the differentiation of 
cytotoxic and inflammatory macrophage/microglia first 
by secretion of pro-inflammatory cytokines and then by 
the destruction of anti-inflammatory tumor associated 
macrophage/microglia. As we utilized athymic nude 
rats, the possible influence of regulatory T cells could 
be underestimated. Nonetheless, to develop effective 
immunotherapy strategies for aggressive GBM tumors 
necessitates use of preclinical models that exhibit similar 
cellular heterogeneity, invasive behavior, and express 
appropriate tumor antigens. Our patient derived P3-30 
GBM model fulfills these requirements, however requires 
propagation in athymic rats. Apart from diminished T 
cells, the other immune cells are representative and fully 
functional [68]. The alternative to xenotransplantation 
would have been to use syngeneic models, where the entire 
immune system is intact. However, as we are targeting 
human NG2/CSPG4 with an anti-human mAb9.2.27, this 
model would not be appropriate due to poor recognition 
of NG2/CSPG4 from rat origin by mAb9.2.27. Since 
pro-inflammatory microglia are implicated in several 
brain diseases [69, 70], future work will have to verify 
the safety and tolerability of our combination treatment 
prior to clinical application. In a potential future clinical 
trial, we envision that our combination NK+mAb9.2.27 
immunotherapy would be administered locally after 
surgical debulking and concurrent temozolomide and 
radiotherapy treatment. In conclusion, administering NK 
cells as adjuvant treatment might be a useful strategy for 
increasing the therapeutic efficacy of several mAb-based 
passive immunotherapies and thereby  positively impact 
the survival of GBM patient.
MATERIALS AND METHODS
Tumor cell lines and their culture, Patient Biopsy
The human GBM cell line U251-NG2 over-
expressing NG2/CSPG4 [8] was originally derived from 
U251. The U251, U87MG (American Type Culture 
Collection, Rockville, MA) and HF66 (Ford Cancer 
Centre, Detroit, MI) GBM cell lines were propagated 
as previously described [8]. The GBM biopsies were 
obtained from surgical resections performed at Haukeland 
University Hospitals. The local ethical board (REK Vest) 
and the Data Protection Agency in Norway approved the 
collection of tumor tissue. Patients gave their informed 
consent to specimen collection for research purposes and 
their samples were analyzed anonymously. 
Antibody PEGylation 
The azide free mAb9.2.27 (10mg/ml) against the 
cell surface chondroitin sulphate proteoglycan NG2 
was a generous gift from Professor Reisfeld (Scripps 
Research Institute, La Jolla, San Diego, CA). Since 
the mAb9.2.27 is an anti-human mouse IgG2a isotype 
known to bind weakly to Fc receptors on effector cells 
[71], polyethylene glycol (PEG) was conjugated to 
the mAb in order to increase its interaction with the Fc 
receptor (FcγRIII) on the effector cells [72]. An aliquot 
of this antibody was PEGylated by 10 times dilution with 
a 24 % PEG 20,000 (Sigma Aldrich, Bornem, Belgium) 
solution (DMEM supplemented with 10 % FBS) for at 
least 30 min at 4 °C. The pegylated reaction was mixed 
with a 4 X Tris-HCl 0.1 M Buffer (pH 7) containing 4 
% SDS, 40 % Glycerol, 0.001 % Bromophenol Blue and 
1 % Beta-Mercaptoethanol and then charged in a 7.5 % 
acrylamide gel and electrophoresis was performed at 60 
mV/gel in SDS-PAGE system. We demonstrated that the 
mAb9.2.27 was successfully PEGylated by approximately 
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2 molecules of the 20 kDa PEG, as revealed by Comassie 
blue staining (Supplementary Fig. 6A). To investigate the 
ability of mAb9.2.27 to crosslink the NK cell FcγRIII, NK 
cells were pre-armed with PEGylated mAb9.2.27, native 
mAb9.2.27 or alone and analyzed by flow cytometry. 
Only pre-arming NK cells with PEGylated mAb9.2.27 
facilitated ligation of the FcγRIII. Incubation with native 
mAb9.2.27 or 24 % PEG alone did not result in specific 
recognition of NK cell FcγRIII (Supplemental Fig. 6B). 
We also investigated the ability of the mAb9.2.27 to 
crosslink the FcγR on purified microglia, the major brain 
effectors. The PEGylated mAb9.2.27 had greater affinity 
for microglia compared to NK cells, and other controls 
(Supplemental Fig. 6C). 
Animals and intracranial implantation
8-10 week old immunodeficient athymic nude rats 
were bred from Hsd:RH-Foxn1 rnu/+ female and Hsd:RH-
Foxn1 rnu male breeding pairs. Rats of both sexes were 
used for tumor implantation and were maintained as 
previously described [8]. This athymic nude rat strain has 
autosomal recessive mutation on rnu locus of chromosome 
10 [73]. It is deficient for some T-cell subpopulations, 
but has normal B-cell function [74], increased NK cell 
number [75] and macrophage cell populations [74]. 7-11 
week old immunocompetent LEWIS (LEW/HanTMHsd; 
Harlan, Horst, The Netherlands) male rats were also used 
for in vitro assays. All animal procedures were performed 
in accordance with protocols approved by The National 
Animal Research Authority (Oslo, Norway). A burr-hole 
was made 1 mm posterior to the bregma and 3 mm to 
the right of the sagittal suture using a micro-drill with a 
bit diameter of 2.9 mm. A Hamilton syringe with inner 
diameter of 810 μm was introduced to a depth of 2.5 mm 
below the brain surface, and the spheroids were slowly 
injected and the syringe left in place for 3 min before 
withdrawal.15 tumor spheroids (each containing 30,000 
cells) were selected under a stereo light microscope. 25 
animals were xenografted with U251-NG2, 28 animals 
with U87MG and 28 animals with patient GBM biopsy 
spheroids from patient 3 (P3-30) that had been serially 
in vivo passaged as previously described [76]. The skin 
was closed with an Ethilon 3-0 suture. The tumors were 
allowed to grow for 3 weeks prior to intra-lesional 
treatment with mAb9.2.27, NK cells from littermates (2 
million cells) or combined NK+mAb9.2.27. Antibodies 
and NK cells were administered using a 26-gauge 
cannula connected to an infusion catheter of an osmotic 
mini pump (Alzet Inc.,) or a syringe, respectively, 
to the same coordinates as were used for the tumor 
implantation procedure. The animals were sacrificed 
at the onset of neurological symptoms of lethargy and 
paralysis in order to obtain overall survival information. 
An additional cohort of 31 animals xenografted with P3-
30 spheroids and treated with NK+mAb9.2.27 with or 
without liposome-encapsulated clodronate was sacrificed 
at set time points as controls by CO2 inhalation and 
decapitation. Their brains were removed, dissociated into 
single cell suspensions or fixed in 4 % formalin for the 
characterization of immune cells infiltrating the brain by 
flow cytometry and/or immunohistochemistry.
Macrophage depletion by clodronate treatment
Depletion of macrophages was done by 
intraperitoneal injection (IP) of 1 ml/100 g body weight 
using 5 mg/ml of liposome-encapsulated clodronate 
(Encapsula NanoScience). The injections were repeated 
weekly for 4 weeks after treatment or until development 
of neurological symptoms. Control rats were injected 
with same volume of PBS or control liposome at the 
same time. Depletion of macrophages was confirmed 
on splenocytes for P3-30 xenografted rats by flow 
cytometric determination of ED1 and ED2 positive cells 
(supplementary Fig. 7A and 7B). It should be noted that 
the IP injection of liposome-encapsulated clodronate 
could not deplete resident microglia (Supplementary 
Fig. 7C). It was demonstrated by several groups that the 
microglia depletion could only be achieved by intracranial 
administration of liposome-encapsulated clodronate 
[77, 78]. Indeed, we drastically decreased the CD11b/
c+CD45high macrophages recruited to the brain in context 
of brain tumor, without major modification of CD11b/
c+CD45low microglia population (Supplementary Fig 7C).
Convection enhanced delivery of mAb9.2.27 
Azide free mAb9.2.27 (4 mg/ml in 24 % PEG 
solution) and IgG2a isotype controls were administered 
through a 26-gauge cannula connected to an osmotic mini 
pump (AD01; Alzet Inc., Mountainview, CA). The pumps 
were installed into the same coordinates as the tumor using 
a stereotactic frame and infused at a CED rate of 8 µl/h 
over 24 h. 
Magnetic resonance imaging
MRI images were obtained with a 7 Tesla Bruker 
Pharmascan (Bruker Biospin, Ettlingen, Germany) using a 
38 mm rat head volume coil for transmitting and receiving 
as previously described [79]. T1-weighted MR imaging 
was obtained using a RARE (rapid acquisition relaxation 
enhancement) sequence with TR = 1.300 ms, TE = 8.86 
ms, rare factor = 4, matrix size = 256 × 256, pixel size = 
137 × 137 µm2, a slice thickness of 1.5 mm (eight slices, 
no gap) and 6 averages. 0.2 mmol/kg Omniscan® contrast 
agent (gadodiamide, MW 0.58 kDa, GE Healthcare, 
Norway) was injected through the tail vein. 
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Histology, immunohistochemistry and 
quantification. 
Brains were formalin fixed, paraffin embedded, 
and every 20th, 3-5μm thick tissue section was stained 
with haematoxylin and eosin. Consecutive sections 
were immunohistochemically stained with various 
mAb: anti-IFNγ (AbDSerotec, Oxford, UK) anti-MIB-1 
(Ki67, Dako, Glostrup, Denmark), rat specific anti-CD8 
(OX-8, AbDSerotec,), anti-CD68 (ED1, AbDSerotec), 
anti-granzyme B, polyclonal anti-myeloperoxidase, 
anti-CD3 (Dako), using the ABC method with 3, 
3”-Diaminobenzidine (DAB) and H2O2 (DCS, Hamburg, 
Germany). Percentages of CD8, Granzyme B, and 
MPO+ immune cells against the negative, haematoxylin 
counterstained nuclei were quantified in at least 10 
fields of view/per section for all the animals in each 
group. Immunohistochemically stained sections were 
segmented and quantified with the use of CellProfiler 
software package [80] and custom made image 
analysis pipelines. Hematoxylin and DAB staining 
were separated by the use of the UnmixColors module. 
Thereafter the CorrectIlluimination module applied an 
illumination correction in order to adjust uneven light 
illumination of the image.  Hematoxyllin stained nuclei 
and positive DAB stained cells were identified using the 
IdentifyPrimaryObjects module with the Otsu Global 
threshold method. For assessing the precision of the 
segmentation, the images were saved with an overlay of 
the segmentation masks. For further details, the specific 
custom-made pipelines used with CellProfilerare 
attached in the supplementary files.
ED1 positivity was assessed using morphometry 
with NIS Elements v 4.0 software and Nikon Eclipse 600 
microscope (Nikon). Semi-quantification of DAB staining 
by morphometry on immunohistochemistry was based 
on signal intensity of ED1 positivity relative to negative 
control section that was set as threshold. The threshold was 
stored and subsequently applied with identical microscope 
settings for scoring of all tumor sections. Immune positive 
elements (pixels above threshold) were measured and 
expressed as area fraction of the visual field for each tumor 
section. For delimitation of the tumor regions core vs. 
periphery, 100 mm from the normal brain boundary was 
defined as periphery for all samples using a grid tool. The 
fraction of Ki67 positive against Ki67 negative tumor cells 
(Ki67 labeling index) was quantified in 5 microscopic high 
power fields (400 X magnification) in all animals in the 
study group. Detection of apoptotic cells was performed 
with the terminal deoxynucleotidyltransferase mediated 
nick endlabeling (TUNEL) assay according to the 
manufacturer’s instructions (Roche Applied Bioscience, 
Mannheim, Germany) and apoptotic cells were quantified 
as previously described [79]. 
NK cell purification and culture
Rat NK cells were purified by negative selection and 
cultured for 4-5 days with 1000 U/ml of IL-2 as previously 
described [17].
TAMs and naïve microglia purification and 
culture
Human biopsy tissue and rat brain were dissected 
from the meninges and mechanically dissociated 
as previously described [6]. Rat homogenates were 
centrifuged and the pellet was suspended in 50 % isotonic 
Percoll (GE Healthcare, Brabant, Belgium), and then 
layered on the top of 70 % isotonic Percoll, and then 
1XPBS was gently layered on the top.  For human TAM 
isolation we used 40 % and 60 % isotonic Percoll gradient. 
After centrifugation at 1,200 × g for 35 min, microglia 
were collected at the interface between the 70 and 50 % 
for rat or 60 % and 40 % for human, isotonic Percoll. The 
purity of TAMs was always superior to 90 %. TAMs and 
naïve microglia were used directly for cytotoxicity assays 
against U87MG, HF66 and P3-30 or adjusted at 2.106 
cells/ml and cultured for 18 h or 96 h in complete RPMI-
1640, or complete medium supplemented 100 ng/ml of 
rat IFN-γ (R&D Systems) (M1-like microglia) or GBM 
supernatant to get M2-like microglia.
Flow cytometry staining
Rat cells were stained for surface antigens using: 
APC-Cy7–conjugated anti-CD45 (OX-1, Biolegend, 
DS Uithoorn, The Netherlands), Alexa 647-conjugated 
anti-NKRP1 (10/78, Biolegend), or anti-CD163 (ED2, 
AbD Serotec), APC-conjugated anti-CCR2 (475301, 
R&D Systems), PE-Cy7-conjugated anti-CD8 (OX-8, 
eBioscience), PerCP-efluor 710-conjugated anti-CD11b/c 
(OX-42, eBioscience), PE-conjugated anti-CD3 (G4.18, 
eBioscience), or anti-CD86 (24F, Biolegend), or anti-
CCR7 (polyclonal, Abcam) coupled to goat anti-rabbit 
PE conjugated F(ab’)2 (Jackson Immunoresearch), Alexa 
Fluor 488-conjugated anti-CD62L (OX-85, Biolegend), or 
FITC-conjugated anti-CD4 (OX-38, Biolegend) or anti-
MHC class II (HIS19, eBioscience). All samples were 
stained with LIVE/DEAD fixable Yellow (Invitrogen) 
in order to gate out dead cells. Then the cells were 
fixed and permeabilized using CytofixCytoperm 
solution (BD Biosciences) before staining with Alexa 
fluor 700-conjugated anti-CD68 (ED1, abD Serotec). 
Interferon-γ production was monitored by intracellular 
FACS staining after the addition of Golgi Plug (BD 
Biosciences) for 5h with FITC-conjugated anti-IFN-γ 
(DB-1, BD Pharmingen). Human isolated TAM were 
stained using FITC-conjugated CD11b (Immuno 
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Tools), V450-conjugated CD45 (BD Biosciences) and 
PERCPCy5.5-conjugated CCR2 (Biolegend). Finally, 
before data acquisition using FACS Fortessa (BD 
Biosciences, Erembodegem, Belgium), nucleated cells 
were stained using Sytox blue (Invitrogen).Data analysis 
was performed using FACSDiva Software version 6.1.2 
(BD Biosciences) and picture and histograms overlays 
were done on Flowjo (Tree Star).
Cytotoxicity assays 
The cytotoxicity assays were performed as 
previously described [17].  Briefly, NK cell cytotoxicity 
was determined after 4 days in culture with 1,000 U/ml 
of IL-2, and microglia cytotoxicity was performed with 
resting cells, differentiated microglia after activation 
with IFN-γ  or as TAMs against the U87MG, HF66 and 
P3-30 target cells labeled with 5µM of CFSE (Sigma 
Aldrich), pre-incubated or not with 1mg/ml of PEGylated 
mAb9.2.27. Effector cells (E) were mixed with target cells 
(T) at E/T ratios of 2/1. After 18 h incubation at 37 °C, 
cells were analyzed on a FACSCanto flow cytometer. To 
identify dead cells, 15 µM of the dead cell marker TO-
PRO-3 was added. At least 2,500 target cells per sample 
were examined.
Cytokine measurements
The levels of IL-1α, IL-6, IL-10, IFN-γ, and TNF-α 
in CSF of untreated control rats, athymic rats treated with 
mAb9.2.27 alone or NK+mAb9.2.27 and cytotoxicity 
assay culture supernatants from NK, NK+GBM cells or 
GBM cells only were measured by CBA (BD Biosciences) 
according to the manufacturer’s protocol. The levels of 
MCP-1 and MCP-3 in plasma were performed with ELISA 
kit from eBioscience and USCN Life Science according to 
manufacturer ´s protocol.
Statistical analysis
All results were expressed as mean± SEM from at 
least three independent experiments. A probability level of 
≤0.05 was considered significant. We used One-Way (with 
Tukey’s Multiple Comparison Test) or Two-Way (with 
Bonferroni a priori Post-hoc test) analysis of variance 
(ANOVA) with post-hoc analyses for comparisons of more 
than 2 groups or variables. Survival was analyzed using 
the Kaplan-Meier and the log rank test using Graphpad 
Prism 5.0 (Graphpad Software, La Jolla, CA).
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